Gathering the record
Relay is organizing the evidence and source boundaries.
Oxyntomodulin-derived glucagon / GLP-1 dual receptor agonist
Mazdutide is a once-weekly glucagon/GLP-1 dual agonist approved in China for chronic weight management and type 2 diabetes. Large Chinese Phase 3 trials support weight and glycemic effects, while evidence outside Chinese populations and long-term outcomes remain limited.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Mazdutide is a medicine designed to influence two metabolic hormone signals involved in appetite, blood sugar, and energy use. It is approved in China, but not by the FDA.
Researchers are examining whether its combined gut-hormone and energy-regulation signals can change weight and diabetes measures, and whether results seen in Chinese development programs extend to other populations.
Several randomized Phase 3 trials in Chinese adults have reported average weight reduction and better blood-sugar measures. Those results support the Chinese approvals for chronic weight management and type 2 diabetes within the products and populations reviewed there.
Generalizability outside the studied Chinese populations, cardiovascular and kidney outcomes, rare harms, long-term maintenance, and regulatory conclusions in other regions remain uncertain. Chinese product evidence does not validate independent research-market vials.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A published Phase 3 trial investigated mazdutide for weight management in Chinese adults with obesity or overweight plus a related condition.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Large randomized Chinese trials support weight and glycaemic outcomes, followed by country-specific approvals.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Results are consistent, while broader generalizability and outcomes trials remain incomplete.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The evidence comes from a Chinese population and a defined clinical-trial program. Regional approval and trial material do not establish FDA approval or equivalence to an independently sourced product. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Multiple randomized Phase 3 trials in Chinese adults, including a 610-participant obesity trial published in NEJM and Phase 3 diabetes studies.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Generalizability beyond studied Chinese populations, cardiovascular and kidney outcomes, rare-event safety, long-term maintenance, and regulatory evidence in other regions.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Its mechanism differs from GLP-1-only agents and from GIP/GLP-1 dual agonists.
Both 4 mg and 6 mg groups lost significantly more weight than placebo through 48 weeks.
The study reported sustained weight reduction and improvement in several metabolic markers.
Mazdutide has direct diabetes-treatment evidence rather than weight-only extrapolation.
This is a real country-specific approval, not a global or U.S. approval.
Approval depends on a specific manufacturer, formulation, quality system, indication, and regulator.
Mechanisms
Mazdutide (IBI362; LY3305677) is an oxyntomodulin-derived dual agonist at GLP-1 and glucagon receptors. In the 610-participant GLORY-1 Phase 3 trial, treatment-policy mean weight change at week 32 was −10.09% and −12.55% for 4 mg and 6 mg versus +0.45% placebo; efficacy-estimand week-48 reductions reached −12.05% and −14.84%. The 462-participant GLORY-2 9 mg trial later reported sustained mean weight reduction at 60 weeks and cardiometabolic improvements. Phase 3 diabetes studies showed substantial HbA1c and weight reductions. China’s NMPA approved mazdutide for chronic weight management in June 2025 and type 2 diabetes in September 2025. The evidence is regionally strong but does not establish FDA approval, global generalizability, cardiovascular-event benefit, or equivalence of non-approved products.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind, placebo-controlled trial
Chinese adults with moderate-to-severe obesity, including a minority with type 2 diabetes
The 9 mg group had sustained clinically meaningful weight reduction and improved several cardiometabolic markers versus placebo.
Study administration: Once-weekly mazdutide 9 mg after protocol titration or placebo
Limitations: One regional trial cannot establish global benefit-risk, cardiovascular-event reduction, or long-term maintenance after treatment.
Randomized, double-blind, placebo-controlled diabetes trial
Chinese adults with type 2 diabetes
Mazdutide produced larger HbA1c reductions than placebo and simultaneous body-weight reductions.
Study administration: Once-weekly mazdutide 4 mg, 6 mg, or placebo
Limitations: The study does not establish cardiovascular outcomes or equivalence to approved therapies outside the studied population.
Randomized, double-blind, placebo-controlled trial
Chinese adults with obesity or overweight plus a comorbidity
At week 48, efficacy-estimand mean weight change was −12.05% and −14.84% versus −0.47% with placebo.
Study administration: Once-weekly mazdutide 4 mg, 6 mg, or placebo under trial protocols
Limitations: The trial was conducted in Chinese adults; outcomes, titration, and product standards cannot be assumed identical in other populations or products.
Randomized, double-blind, placebo-controlled dose-finding trial
Chinese adults with overweight or obesity
Mazdutide up to 6 mg produced robust dose-dependent weight reduction over 24 weeks.
Study administration: Multiple once-weekly mazdutide dose regimens or placebo
Limitations: Phase 2 duration was short, and the study preceded the approved Chinese product program.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryApproved in China for chronic weight management and type 2 diabetes; not FDA approved Generalizability beyond studied Chinese populations, cardiovascular and kidney outcomes, rare-event safety, long-term maintenance, and regulatory evidence in other regions.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-06-08 · PMID 42251595 · DOI 10.1001/jama.2026.8142
2025-12-01 · PMID 41407859
2025-09-19
2025-06-27
2025-05-25 · PMID 40421736 · DOI 10.1056/NEJMoa2411528
2023-12-08 · NCT06164873
2023-12-01 · PMID 38092790